We are live on
!
Find out more
CUAMC
China Universal Asset Management Company Portfolio holdings
AUM
$1.67B
1-Year Est. Return
89%
This Fund
S&P 500
This Quarter
Est. Return
+11.72%
1 Year Est. Return
+89%
3 Year Est. Return
+264.17%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$249M
AUM Growth
+$11.2M
(+4.7%)
Cap. Flow
+$1.58M
Cap. Flow
% of AUM
0.64%
Top 10 Holdings %
Top 10 Hldgs %
35.47%
Holding
513
New
48
Increased
266
Reduced
45
Closed
120
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
iQIYI
IQ
|
+$7.05M |
| 2 |
Amazon
AMZN
|
+$3.89M |
| 3 |
uniQure
QURE
|
+$2.86M |
| 4 |
BioNTech
BNTX
|
+$2.81M |
| 5 |
DexCom
DXCM
|
+$2.78M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Tesla
TSLA
|
+$5.6M |
| 2 |
Procter & Gamble
PG
|
+$3.27M |
| 3 |
NVO
Novo Nordisk
NVO
|
+$3.16M |
| 4 |
CVS Health
CVS
|
+$3.1M |
| 5 |
Alphabet (Google) Class A
GOOGL
|
+$2.85M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 35.23% |
| 2 | Healthcare | 25.2% |
| 3 | Consumer Discretionary | 20.47% |
| 4 | Communication Services | 8.05% |
| 5 | Financials | 3.36% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
151
Intellia Therapeutics
NTLA
$1.69B
| $33.3K | 0.01% |
954
+88
| +10% | +$4.18K |
|
152
Harmony Biosciences
HRMY
$2.32B
| $33.2K | 0.01% |
603
+49
| +9% | +$2.69K |
|
153
Ultragenyx Pharmaceutical
RARE
$2.65B
| $33K | 0.01% |
712
+56
| +9% | +$2.2K |
|
154
Legend Biotech
LEGN
$3.99B
| $32.8K | 0.01% |
658
+159
| +32% | +$7.7K |
|
155
Prothena Corp
PRTA
$475M
| $29.6K | 0.01% |
491
+52
| +12% | +$3.04K |
|
156
AbCellera Biologics
ABCL
$3.18B
| $29.4K | 0.01% |
2,906
+236
| +9% | +$2.73K |
|
157
PTC Therapeutics
PTCT
$6.06B
| $27.9K | 0.01% |
731
+61
| +9% | +$2.54K |
|
158
Insmed
INSM
$28.9B
| $27.5K | 0.01% |
1,376
+252
| +22% | +$4.87K |
|
|
BPMC
159
DELISTED
Blueprint Medicines
BPMC
| $26.6K | 0.01% |
608
+49
| +9% | +$2.35K |
|
|
MRTX
160
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $26.5K | 0.01% |
585
+64
| +12% | +$4.14K |
|
|
ISEE
161
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| $26.3K | 0.01% |
1,227
+121
| +11% | +$2.58K |
|
162
Acadia Pharmaceuticals
ACAD
$5.07B
| $26.2K | 0.01% |
1,645
+130
| +9% | +$2.03K |
|
|
AKRO
163
DELISTED
Akero Therapeutics
AKRO
| $26K | 0.01% |
475
+123
| +35% | +$5.27K |
|
164
Xenon Pharmaceuticals
XENE
$6.31B
| $25K | 0.01% |
635
+52
| +9% | +$1.89K |
|
165
Amylyx Pharmaceuticals
AMLX
$2.6B
| $24.9K | 0.01% |
+673
| New | +$23.9K |
|
166
Immunovant
IMVT
$8.8B
| $23.3K | 0.01% |
1,312
+220
| +20% | +$2.77K |
|
|
SAGE
167
DELISTED
Sage Therapeutics
SAGE
| $23.1K | 0.01% |
605
+49
| +9% | +$1.87K |
|
168
BioCryst Pharmaceuticals
BCRX
$2.71B
| $21.7K | 0.01% |
1,893
+152
| +9% | +$1.9K |
|
169
Zai Lab
ZLAB
$2.86B
| $21.5K | 0.01% |
701
+51
| +8% | +$1.61K |
|
170
Revolution Medicines
RVMD
$44B
| $21.5K | 0.01% |
902
+81
| +10% | +$1.72K |
|
171
Krystal Biotech
KRYS
$9.85B
| $20.8K | 0.01% |
262
+22
| +9% | +$1.63K |
|
172
ImmunityBio
IBRX
$8.2B
| $20.6K | 0.01% |
4,067
+318
| +8% | +$1.75K |
|
173
Supernus Pharmaceuticals
SUPN
$2.78B
| $19.6K | 0.01% |
549
+48
| +10% | +$1.67K |
|
174
Charles River Laboratories
CRL
$13.6B
| $19.4K | 0.01% |
89
-11,677
| -99% | -$2.55M |
|
175
Ironwood Pharmaceuticals
IRWD
$714M
| $19.3K | 0.01% |
1,558
+123
| +9% | +$1.4K |
|
Similar funds
HA
JPM
CPO
LCI
GWM
JIP
RMC
GACM
China Universal Asset Management Company's Q4 2022 Portfolio in Review
As of Q4 2022, China Universal Asset Management Company held 513 positions worth $249M, up 4.7% from $238M the previous quarter. Its ten largest holdings account for 35% of the portfolio.
China Universal Asset Management Company's Q4 2022 filing shows 48 new, 266 increased, 45 reduced and 120 closed positions. Its largest new stake was iQIYI: 2,418,500 shares worth $12.8M. The largest sale was Tesla, an estimated $5.6M.
By sector, the portfolio is most concentrated in Technology at 35% of assets, down from 36% a quarter earlier, followed by Healthcare and Consumer Discretionary.
- China Universal Asset Management Company's largest Q4 2022 buy was iQIYI: 2,418,500 shares worth $12.8M.
- China Universal Asset Management Company added most to Amazon in Q4 2022, an estimated $3.89M increase.
- China Universal Asset Management Company's biggest Q4 2022 reduction was Tesla, cutting an estimated $5.6M.
- China Universal Asset Management Company fully exited Sprott Physical Gold in Q4 2022, selling an estimated $2.3M.
- China Universal Asset Management Company's ten largest holdings make up 35% of its $249M portfolio in Q4 2022.
- China Universal Asset Management Company opened 48 new positions and closed 120 in Q4 2022.
- China Universal Asset Management Company's portfolio value rose 4.7% quarter-over-quarter to $249M.
Based on China Universal Asset Management Company's 13F filing for Q4 2022, filed 31 Jan 2023.